Pfizer/OSI To Curtail Macugen Research In Response To Genentech Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will wind down select Phase III trials for Macugen to reallocate resources toward positioning the AMD treatment as a maintenance therapy.
You may also be interested in...
Genaera Shifts Focus From AMD To Obesity
Company switches gears in the wake of Genentech’s Lucentis launch.
Genaera Shifts Focus From AMD To Obesity
Company switches gears in the wake of Genentech’s Lucentis launch.
Pfizer Boosts RNAi Interest With Sigma-Aldrich Licensing Agreement
Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.